A Pilot Study Investigating the Effect of Omalizumab (Xolair) in Work-Related Animal Induced Asthma
Status:
Withdrawn
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
Management of animal induced occupational asthma is mainly avoidance, but this is not
feasible for many occupations. Treatment with avoidance and conventional treatment is also
not always successful. Omalizumab is FDA approved for the treatment of allergic asthma and
may be effective at reducing symptoms and disease progression in the animal handlers
population.